Vestal Point Capital, LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001974915

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q1 2025 · 63 positions · Total reported value $1.40B · Top-10 concentration 51.4% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 64.6% · 14 new · 20 cut · 19 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -13.4% · vs SPY -15.5% · Prev Value $4.28B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -2.9% · vs SPY -5.1% · Latest Value $3.87B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q1 2025 13F filing, Vestal Point Capital, LP disclosed 63 equity positions with a combined reported value of $1.40B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 51.4% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q1 2025 were ACLX ($156.63M), CYTK ($104.11M), INSM ($82.01M). By sector, the heaviest allocations are Health Care 64.3%, Industrials 2.7%. Versus the prior quarter, allocation shifted toward Other (+14.2pp), Industrials (+2.1pp) and away from Health Care (-16.3pp).

Versus the prior quarter, Vestal Point Capital, LP opened 14 new positions, trimmed 20 and fully exited 19, a turnover rate of 64.6% of positions. The portfolio's overlap with the prior quarter was 58% of names.

The largest new positions opened in Q1 2025 were CRNX ($50.31M), SRRK ($41.80M), DHR ($25.62M).

Of the 19 positions fully exited versus the prior quarter, the largest were JAZZ ($120.07M), MRK ($79.58M), BMRN ($56.53M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q1 2025)

  • CRNX CRINETICS PHARMACEUTICALS IN · $50.31M
  • SRRK SCHOLAR ROCK HLDG CORP · $41.80M
  • DHR DANAHER CORP DEL · $25.62M
  • DYN DYNE THERAPEUTICS INC · $18.83M
  • COGT COGENT BIOSCIENCES INC · $17.97M
  • GEHC GE HEALTHCARE TECHNOLOGIES I · $16.48M
  • BRKR BRUKER CORP · $12.52M
  • CDTX CIDARA THERAPEUTICS INC COM NEW · $10.87M

Fully Exited (vs previous quarter)

  • JAZZ JAZZ PHARMACEUTICALS PLC · prev qtr: $120.07M
  • MRK MERCK & CO INC · prev qtr: $79.58M
  • BMRN BIOMARIN PHARMACEUTICAL INC · prev qtr: $56.53M · history
  • SLNO SOLENO THERAPEUTICS INC · prev qtr: $47.65M
  • SNY SANOFI SA · prev qtr: $36.17M · history
  • GSK GSK PLC · prev qtr: $33.82M
  • AZN ASTRAZENECA PLC · prev qtr: $31.12M
  • MDGL MADRIGAL PHARMACEUTICALS INC · prev qtr: $29.31M

Insider Transactions (Form 4)

Latest Vestal Point Capital, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Vestal Point Capital, LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q3 2026 it reported 63 US equity positions with a combined value of $3.87B. HoldingsHub carries 12 quarters of its filings (Q4 2023–Q3 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-127682 (status: Approved), registered 2023-04-14
  • Regulatory AUM (Form ADV): $5.47B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 1 private funds, of which 1 hedge funds
  • Website: vestalpoint.com

Portfolio Structure

  • 63 positions · $3.87B reported value (Q3 2026)
  • Top 10 holdings = 67.3% of reported value
  • Largest position: ABVX (ABIVAX SA) at 10.1%
  • Average position size: $61.44M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 14 new, 22 added, 20 reduced, 19 exited
  • 7 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 64.3%
Other 33.0%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 2.39M $156.63M 11.19%
11.19%
Add
2 2.59M $104.11M 7.43%
7.43%
Add
3 1.07M $82.01M 5.86%
5.86%
Add
4 1.07M $76.24M 5.44%
5.44%
Add
5 2.50M $60.05M 4.29%
4.29%
Add
6 4.75M $54.83M 3.92%
3.92%
Hold
7 4.79M $50.80M 3.63%
3.63%
Add
8 1.50M $50.31M 3.59%
3.59%
New
9 1.30M $43.62M 3.12%
3.12%
Add
10 1.30M $41.80M 2.98%
2.98%
New
11 2.77M $36.08M 2.58%
2.58%
Add
12 22.01M $34.99M 2.50%
2.50%
Add
13 4.28M $34.88M 2.49%
2.49%
Add
14 7.19M $32.44M 2.32%
2.32%
Add
15 1.79M $30.97M 2.21%
2.21%
Add
16 1.70M $30.84M 2.20%
2.20%
Add
17 11.00M $30.47M 2.18%
2.18%
Add
18 2.88M $26.78M 1.91%
1.91%
Add
19 125.00K $25.62M 1.83%
1.83%
New
20 2.15M $23.81M 1.70%
1.70%
Add
21 150.14K $23.40M 1.67%
1.67%
Reduce
22 4.18M $22.32M 1.59%
1.59%
Hold
23 2.60M $20.60M 1.47%
1.47%
Add
24 1.80M $18.83M 1.34%
1.34%
New
25 500.00K $18.11M 1.29%
1.29%
Reduce
26 1.23M $18.10M 1.29%
1.29%
Reduce
27 3.00M $17.97M 1.28%
1.28%
New
28 433.19K $17.68M 1.26%
1.26%
Add
29 267.63K $16.99M 1.21%
1.21%
Reduce
30 587.65K $16.48M 1.18%
1.18%
Add
31 204.13K $16.48M 1.18%
1.18%
New
32 2.32M $16.19M 1.16%
1.16%
Reduce
33 200.00K $14.64M 1.04%
1.04%
Reduce
34 1.13M $13.37M 0.95%
0.95%
Add
35 200.00K $12.76M 0.91%
0.91%
Reduce
36 300.00K $12.52M 0.89%
0.89%
New
37 504.54K $10.87M 0.78%
0.78%
New
38 5.60M $8.68M 0.62%
0.62%
Hold
39 200.00K $7.81M 0.56%
0.56%
New
40 1.75M $6.49M 0.46%
0.46%
Reduce
41 350.00K $5.98M 0.43%
0.43%
Add
42 500.00K $5.96M 0.42%
0.42%
Add
43 11.50M $5.62M 0.40%
0.40%
Hold
44 900.00K $5.37M 0.38%
0.38%
Hold
45 200.00K $5.02M 0.36%
0.36%
Add
46 1.25M $4.22M 0.30%
0.30%
Add
47 1.14M $3.94M 0.28%
0.28%
Reduce
48 169.86K $3.77M 0.27%
0.27%
New
49 198.65K $3.61M 0.26%
0.26%
Reduce
50 635.00K $2.73M 0.20%
0.20%
Hold

FAQ

What did Vestal Point Capital, LP buy in 2025-Q1?

In its 2025-Q1 13F filing, Vestal Point Capital, LP reported 63 equity positions worth $1.40B in aggregate; its largest disclosed positions were ACLX ($156.63M), CYTK ($104.11M), INSM ($82.01M).

How large is Vestal Point Capital, LP's portfolio?

Vestal Point Capital, LP reported $1.40B of long equity holdings across 63 positions as of 2025-Q1. Top-10 holdings account for 51.4% of reported value.

What is Vestal Point Capital, LP's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/vestal-point-capital/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →